xm:冷颖
xb:女
zc:研究员
xl:博士
dh:+86-
cz:
dzyj:yleng@simm.ac.cn
grzy:
zjlb:研究员；新药；
zw:中科院上海药物所研究员、博士生导师、研究组长
txdz:上海市浦东新区张江高科技园区祖冲之路555号
grjj:冷颖研究员，1999年于中国科学院上海药物研究所获得博士学位， 2002-2003年于瑞典Karolinska Institute开展博士后研究，2005年起任中国科学院上海药物研究所研究员、研究组长、博士生导师。从事抗糖尿病和代谢性疾病（NASH、肥胖等）创新药物发现和作用机理研究，完成20余个抗糖尿病1.1类新药临床前药效研究，获授权和申请国内外发明专利20余项，发表SCI收录论文80余篇。作为课题负责人主持国家自然科学基金、“973”重点基础研究发展计划课题、“重大新药创制”国家科技重大专项候选新药课题、欧洲糖尿病基金会（EFSD）中欧合作课题、上海市科技人才和生物医药重点科技攻关项目等。

yjfx:抗糖尿病和代谢性疾病（NASH、肥胖等）创新药物发现和作用机理研究：

1.利用分子、细胞、组织和转基因动物模型，开展抗糖尿病及代谢性疾病活性先导化合物发现和创新药物研究。

2.从天然产物中发现抗糖尿病和代谢性疾病活性先导化合物，开展新机理和新靶标发现研究。

3.肝脏和骨骼肌糖脂代谢紊乱及胰岛素抵抗发生机制研究。

dblz:1.Liu SW, Huang SL, Wu XD, Feng Y, Shen Y, Zhao QS*, Leng Y*. Activation of SIK1 by phanginin A inhibits hepatic gluconeogenesis by increasing PDE4 activity and suppressing cAMP signaling pathway. Molecular Metabolism 2020 June (In press) https://doi.org/10.1016/j.molmet.2020.101045

2.Ning MM, Yang WJ, Guan WB, Gu YP, Feng Y, Leng Y*. Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. Acta Pharmacol Sin. 2020 May 12. (In press) https://doi.org/10.1038/s41401-020-0413-7

3.Huang S, Ma S, Ning M, Yang W, Ye Y, Zhang L, Shen J*, Leng Y*. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice. Metabolism Clinical and Experimental 2019, 99: 45–56

4.Huang F, Ning M, Wang K, Liu J, Guan W, Leng Y*, Shen J*. Discovery of Highly Polar β-Homophenylalanine Derivatives as Nonsystemic Intestine-Targeted Dipeptidyl Peptidase IV Inhibitors. J Med Chem 2019, 62(23):10919-10925

5.Xie W, Ye Y, Feng Y, Xu T, Huang S*, Shen J*, Leng Y*. Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3. Front Pharmacol. 2018 May 15; 9: 476.

6.Chen T, Ning M, Ye Y, Wang K, Leng Y*, Shen J*. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker. Eur J Med Chem. 2018 May 25; 152:175-194.

7.Huang SJ, Huang SL, Wang X, Zhang QL, Liu J, Leng Y* Downregulation of lipin-1 induces insulin resistance by increasing intracellular ceramide accumulation in C2C12 myotubes. Int. J. Biol. Sci. 2017; 13(1):1-12.

8.Ma SY, Ning MM, Zou QA, Feng Y, Ye YL, Shen JH*, Leng Y*.OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition. Acta Pharmacol Sin. 2016 Sep;37(10):1359-1369.

9.Cao H, Chen ZX, Wang K, Ning MM, Zou QA, Feng Y, Ye YL, Leng Y*, Shen JH*. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect. Sci Rep. 2016 Jun 24;6:28676.

10.Dai YL, Huang SL, Leng Y*.AICAR and Metformin Exert AMPK-dependent Effects on INS-1E Pancreatic β-cell Apoptosis via Differential Downstream Mechanisms. Int J Biol Sci. 2015 Sep 14;11(11):1272-80.

11.Duan H, Ning M, Zou Q, Ye Y, Feng Y, Zhang L, Leng Y*, Shen J*.Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes. J Med Chem. 2015 Apr 23;58(8):3315-28

12.Duan H, Ning M, Chen X, Zou Q, Zhang L, Feng Y, Zhang L, Leng Y*, Shen J*, Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives as Potent and Orally Efficacious TGR5 Agonists. J Med Chem. 2012，55(23):10475-89

13.Huang SL, Yu RT, Gong J, Feng Y, Dai YL, Hu F, Hu YH, Tao YD*, Leng Y*. Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice. Diabetologia. 2012 May;55(5):1469-81.

14.Feng Y, Huang SL, Dou W, Zhang S, Chen JH, Shen Y, Shen JH, Leng Y* Emodin, a natural product, selectively inhibits 11β-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Br J Pharmacol. 2010 ;161(1):113-26

jyjl:1989.09-1993.06南京师范大学生物系,获理学学士学位